The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.
Alzheimer’s disease: Clinical trials and drug development
Abstract
Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although nanoformulations have demonstrated potential in these areas, γ-secretase inhibition has been associated with significant adverse effects due to its involvement in multiple physiological processes.”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [111]
In the citing paper
“The shortness of current agents used against AD can be attributed to several factors and low bioavailability is considered one of the most important ones among them [204].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [204]
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Research works printed but not linked: 3
- Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
- Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
- Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9
Cited by
Sorted by citations
Items 101–200 of 1,000
Zhang, Z., Shen, Q., Wu, X., Zhang, D., & Xing, D. (2019) · Aging Cell · doi:10.1111/acel.13054 · Cited by 142
Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140
Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00284 · Cited by 140
Pathophysiology and management of alzheimer’s disease: an overview
Thakur, A. K., Kamboj, P., Goswami, K., & Ahuja, K. (2018) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2018.07.00230 · Cited by 144
Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration
Uddin, M. S., Mamun, A. A., Kabir, M. T., Ahmad, J., Jeandet, P., Sarwar, M. S., Ashraf, G. M., & Aleya, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173412 · Cited by 139
Liu, P., Zhang, T., Chen, Q., Li, C., Chu, Y., Guo, Q., Zhang, Y., Zhou, W., Chen, H., Zhou, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100746 · Cited by 140
Inflammatory aspects of Alzheimer’s disease
Lucena, P. B., & Heneka, M. T. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02790-2 · Cited by 152
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
Palmer, A. M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.007 · Cited by 136
Convolutional neural networks for Alzheimer’s disease detection on MRI images
Ebrahimi, A., & Luo, S. (2021) · Journal of Medical Imaging · doi:10.1117/1.jmi.8.2.024503 · Cited by 133
Awasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.008 · Cited by 139
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
Hira, S., Saleem, U., Anwar, F., Sohail, M. F., Raza, Z., & Ahmad, B. (2019) · Biomolecules · doi:10.3390/biom9090441 · Cited by 131
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Cytoprotective protein C pathways and implications for stroke and neurological disorders
Zlokovic, B. V., & Griffin, J. H. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.005 · Cited by 128
Zaman, M., Khan, A. N., Wahiduzzaman, Zakariya, S. M., & Khan, R. H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.05.109 · Cited by 135
Xu, Z.-P., Li, L., Bao, J., Wang, Z.-H., Zeng, J., Liu, E.-J., Li, X., Huang, R., Gao, D., Li, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108645 · Cited by 129
Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review
Brown, B. M., Peiffer, J. J., & Rainey‐Smith, S. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.003 · Cited by 130
Vizi, E. S., Kisfali, M., & Lőrincz, T. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.10.005 · Cited by 125
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies
Medina, M., Garrido, J. J., & Wandosell, F. G. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00024 · Cited by 127
Dodel, R. C., Balakrishnan, K., Keyvani, K., Deuster, O., Neff, F., Andrei‐Selmer, L., Röskam, S., Stüer, C., Al‐Abed, Y., Noelker, C., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4401-10.2011 · Cited by 129
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125
Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression
Saito, T., Matsuba, Y., Yamazaki, N., Hashimoto, S., & Saido, T. C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1907-16.2016 · Cited by 121
Pharmacological Treatment of Alzheimer Disease
Massoud, F., & Léger, G. C. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601003 · Cited by 130
Effects of Polyphenols on Brain Ageing and Alzheimer’s Disease: Focus on Mitochondria
Schaffer, S., Asseburg, H., Kuntz, S., Muller, W. E., & Eckert, G. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8282-9 · Cited by 124
Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease–Like Pathology and Cognitive Decline
Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto‐Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., Fisher, A., & LaFerla, F. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.041 · Cited by 120
The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology
Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120
Jin, W., Shen, L., Bu, X., Zhang, W., Chen, S., Huang, Z., Xiong, J., Gao, C., Dong, Z., He, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1721-y · Cited by 121
Rovira‐Llopis, S., Apostolova, N., Bañuls, C., Muntané, J., Rocha, M., & Víctor, V. M. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7313 · Cited by 125
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 121
The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease
Gadhave, K., Bolshette, N. B., Ahire, A., Pardeshi, R., Thakur, K. K., Trandafir, C.-M., Istrate, A., Ahmed, S., Lahkar, M., Muresanu, D. F., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12817 · Cited by 122
Çavdar, H., Şentürk, M., Güney, M., Durdağı, S., Kayık, G., Supuran, C. T., & Ekinci, D. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1543288 · Cited by 121
Role of iron in neurodegenerative diseases
Li, K., & Reichmann, H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1508-7 · Cited by 121
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 119
Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection
Caraci, F., Spampinato, S. F., Sortino, M. A., Bosco, P., Battaglia, G., Bruno, V., Drago, F., Nicoletti, F., & Copani, A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1230-6 · Cited by 116
Bossers, W. J. R., van der Woude, L. H. V., Boersma, F., Scherder, E., & van Heuvelen, M. J. G. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345038 · Cited by 113
Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt277 · Cited by 112
Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty
Kimmelman, J., & London, A. J. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001010 · Cited by 109
Yao, X.-Q., Jiao, S.-S., Saadipour, K., Zeng, F., Wang, Q.-H., Zhu, C., Shen, L.-L., Zeng, G.-H., Liang, C.-R., Wang, J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.49 · Cited by 109
Advances in the prevention of Alzheimer's Disease
Sindi, S., Mangialasche, F., & Kivipelto, M. (2015) · F1000Prime Reports · doi:10.12703/p7-50 · Cited by 118
Self-citationCavedo, E., Grothe, M. J., Olivier Colliot, A., Lista, S., Marie Chupin, A., Dormont, D., Houot, M., Lehéricy, S., Teipel, S. J., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 112
Transfer Learning for Alzheimer's Disease Detection on MRI Images
Ghahnavieh, A. E., Luo, S., & Chiong, R. (2019) · IEEE International Conference on Industry 4.0, Artificial Intelligence, and Communications Technology (IAICT) · doi:10.1109/iciaict.2019.8784845 · Cited by 111
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
“[9] and can be used to compare changes over a 6-year period.”
Fischer, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.038 · Cited by 113
Epigenetic memory: The Lamarckian brain
Fischer, A. (2014) · The EMBO Journal · doi:10.1002/embj.201387637 · Cited by 107
Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides
Bali, J., Gheinani, A. H., Zurbriggen, S., & Rajendran, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201632109 · Cited by 107
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Histone Modifications in Alzheimer’s Disease
Santana, D. A., Smith, M. D. A. C., & Chen, E. (2023) · Genes · doi:10.3390/genes14020347 · Cited by 113
γ-Secretase Associated with Lipid Rafts
Matsumura, N., Takami, M., Okochi, M., Wada‐Kakuda, S., Fujiwara, H., Tagami, S., Funamoto, S., Ihara, Y., & Morishima‐Kawashima, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.510131 · Cited by 103
Zhou, H., Gong, Y., Liu, Y., Huang, A., Zhu, X., Liu, J., Yuan, G., Zhang, L., Wei, J., & Liu, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119822 · Cited by 107
Kang, J., Vanderstichele, H., Trojanowski, J. Q., & Shaw, L. M. J. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.023 · Cited by 109
Soto-Ortega, D. D., Murphy, B. P., Gonzalez‐Velasquez, F. J., Wilson, K. A., Xie, F., Wang, Q., & Moss, M. A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.03.010 · Cited by 104
Cheng, H., Wang, M., Li, J., Cairns, N. J., & Han, X. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12368 · Cited by 103
Ahn, H. J., Glickman, J. F., Poon, K., Zamolodchikov, D., Jno-Charles, O. C., Norris, E. H., & Strickland, S. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131751 · Cited by 103
Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Hubin, E., van Nuland, N. A. J., Broersen, K., & Pauwels, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1634-z · Cited by 102
Applications of brain organoids in neurodevelopment and neurological diseases
Sun, N., Meng, X., Liu, Y., Song, D., Jiang, C., & Cai, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00728-4 · Cited by 103
Quan, S., Fu, X., Cai, H., Ren, Z., Xu, Y., & Jia, L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00815-2 · Cited by 110
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 103
Dinamarca, M. C., Ríos, J. A., & Inestrosa, N. C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00464 · Cited by 105
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000041 · Cited by 101
Targeting intrinsically disordered proteins in rational drug discovery
Ambadipudi, S., & Zweckstetter, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1107041 · Cited by 101
Flores, J., Noël, A., Foveau, B., Beauchet, O., & LeBlanc, A. C. (2020) · Nature Communications · doi:10.1038/s41467-020-18405-9 · Cited by 103
Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review
Nie, J., Gao, Q., Fu, J., & He, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901773 · Cited by 100
Alzheimer's disease: β‐amyloid plaque formation in human brain
Seeman, P. M., & Seeman, N. (2011) · Synapse · doi:10.1002/syn.20957 · Cited by 103
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
Prospective memory function in mild cognitive impairment and early dementia
Thompson, C. L., Henry, J. D., Rendell, P. G., Withall, A., & Brodaty, H. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709991354 · Cited by 102
Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau
Takahashi, M., Miyata, H., Kametani, F., Nonaka, T., Akiyama, H., Hisanaga, S., & Hasegawa, M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1415-2 · Cited by 101
Parthsarathy, V., McClean, P. L., Hölscher, C., Taylor, M., Tinker, C. L., Jones, G., Kolosov, O., Salvati, E., Gregori, M., Masserini, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054769 · Cited by 96
Introducing Transfer Learning to 3D ResNet-18 for Alzheimer’s Disease Detection on MRI Images
Ghahnavieh, A. E., Luo, S., & Chiong, R. (2020) · International Conference on Image and Vision Computing New Zealand (IVCNZ) · doi:10.1109/ivcnz51579.2020.9290616 · Cited by 92
Dimitrov, M. I., Alattia, J., Lemmin, T., Lehal, R., Fligier, A., Houacine, J., Hussain, I., Radtke, F., Peraro, M. D., Beher, D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3246 · Cited by 92
Tamibarotene: A Candidate Retinoid Drug for Alzheimer’s Disease
Fukasawa, H., Nakagomi, M., Yamagata, N., Katsuki, H., Kawahara, K., Kitaoka, K., Miki, T., & Shudo, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00314 · Cited by 91
Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Wang, Z., Hu, J., Yang, X., Feng, X., Li, X., Huang, L., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01417 · Cited by 91
Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 94
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 93
Mitochondrial function in ageing: coordination with signalling and transcriptional pathways
Yin, F., Sancheti, H., Liu, Z., & Cadenas, E. (2015) · The Journal of Physiology · doi:10.1113/jp270541 · Cited by 93
Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease
Mufson, E. J., Counts, S., Ginsberg, S. D., Mahady, L. J., Perez, S. E., Massa, S. M., Longo, F. M., & Ikonomović, M. D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00533 · Cited by 94
Zhao, J., Yin, F., Ji, L., Wang, C., Shi, C., Liu, X., Yang, H., Wang, X., & Kong, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c11064 · Cited by 88
Glial hemichannels and their involvement in aging and neurodegenerative diseases
Orellana, J. A., Rommy von Bernhardi, M., Giaume, C., & Sáez, J. C. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2011-0065 · Cited by 88
Frederiksen, K. S., Gjerum, L., Waldemar, G., & Hasselbalch, S. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170567 · Cited by 86
Wu, Y., Gong, Y., Luan, Y., Li, Y., Liu, J., Yue, Z., Yuan, B., Sun, J., Xie, C., Li, L., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901984r · Cited by 85
Miyamae, Y., Kurisu, M., Murakami, K., Han, J., Isoda, H., Irie, K., & Shigemori, H. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.001 · Cited by 88
Role of Leptin in Mood Disorder and Neurodegenerative Disease
Zou, X., Zhong, L., Zhu, C., Zhao, H., Zhao, F., Cui, R., Gao, S., & Li, B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00378 · Cited by 85
Pouliopoulos, A. N., Kwon, N., Jensen, G., Meaney, A., Niimi, Y., Burgess, M. T., Ji, R., McLuckie, A. J., Muñoz, F., Kamimura, H. A. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94188-3 · Cited by 85
Thenmozhi, A. J., Dhivyabharathi, M., Raja, T. R. W., Manivasagam, T., & Essa, M. M. (2015) · Nutritional Neuroscience · doi:10.1179/1476830515y.0000000016 · Cited by 85
Tahir, S., Ramzan, M. S., Hassan, A., Sadiq, A., Jan, M. S., Khan, F. A., Ullah, F., Ahmad, H., Bibi, M., Mahmood, T., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.035 · Cited by 84
Economic Evaluation of Treatment Options in Patients with Alzheimerʼs Disease
Pouryamout, L., Dams, J., Wasem, J., Dodel, R. C., & Neumann, A. (2012) · Drugs · doi:10.2165/11631830-000000000-00000 · Cited by 82
Deardorff, W. J., Shobassy, A., & Grossberg, G. T. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995639 · Cited by 83
Drugs: A tangled web of targets
Gravitz, L. (2011) · Nature · doi:10.1038/475s9a · Cited by 81
Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions
Ogbodo, J. O., Agbo, C. P., Njoku, U. O., Ogugofor, M. O., Egba, S. I., Ihim, S. A., Echezona, A. C., Brendan, K. C., Upaganlawar, A. B., & Upasani, C. D. (2021) · Current Aging Science · doi:10.2174/1874609814666210302085232 · Cited by 86
Vitamin D in Relation to Cognitive Impairment, Cerebrospinal Fluid Biomarkers, and Brain Volumes
Hooshmand, B., Lökk, J., Solomon, A., Mangialasche, F., Miralbell, J., Spulber, G., Annerbo, S., Andreasen, N., Winblad, B. G., Cedazo-Mı́nguez, Á., et al. (2014) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu022 · Cited by 84
Self-citationMasitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80
Malishev, R., Shaham‐Niv, S., Nandi, S., Kolusheva, S., Gazit, E., & Jelinek, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00438 · Cited by 81
Tan, H.-Y., Qiu, Y.-T., Sun, H., Yan, J., & Zhang, L. (2019) · Chemical Communications · doi:10.1039/c9cc00113a · Cited by 79
Le, X. T., Pham, H. T. N., Do, P. T., Fujiwara, H., Tanaka, K., Li, F., Van Nguyen, T., Nguyen, K. M., & Matsumoto, K. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1129-6 · Cited by 79
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Formaldehyde toxicity in age-related neurological dementia
Kou, Y., Zhao, H., Cui, D., Han, H., & Tong, Z. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101512 · Cited by 82
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors
Michaels, T. C. T., Šarić, A., Meisl, G., Heller, G. T., Curk, S., Arosio, P., Linse, S. S., Dobson, C. M., Vendruscolo, M., & Knowles, T. P. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006684117 · Cited by 76
Yang, M., Jin, L., Wu, Z., Xie, Y., Zhang, P., Wang, Q., Yan, S., Chen, B., Liang, H., Naman, C. B., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c00569 · Cited by 86
NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy
Quraishe, S., Cowan, C. M., & Mudher, A. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.32 · Cited by 76
The BRICHOS Domain, Amyloid Fibril Formation, and Their Relationship
Knight, S. D., Presto, J., Linse, S. S., & Johansson, J. (2013) · Biochemistry · doi:10.1021/bi400908x · Cited by 77
Metadata
- Authors
- Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
- Affiliations
- University of Perugia (IT)
- University of Eastern Finland (FI)
- Karolinska Institutet (SE)
- Corresponding author
- Winblad, Bengt
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 9
- Issue
- 7
- Pages
- 702-716
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2129267808
- Cited by
- 1,217
- References
- 161
- Citations by year
- 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-06-01)
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
